Tandem Diabetes Care (TNDM) Income from Non-Controlling Interests (2014 - 2026)
Tandem Diabetes Care (TNDM) posted Income from Non-Controlling Interests of -$1.0 million for Q1 2026, down 1995.92% on a QoQ basis from -$49000.0 in Q4 2025, and down 342.79% year-over-year from $423000.0 in Q1 2025.
Tandem Diabetes Care (TNDM) Income from Non-Controlling Interests (2014 - 2026) Analysis & Trends
Tandem Diabetes Care's Income from Non-Controlling Interests history runs 11 years deep, the most recent figure standing at -$1.0 million for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 342.79% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$933000.0 (down 166.26% YoY) and the FY2025 annual result came in at $517000.0, up 266.24% from the prior year.
- Income from Non-Controlling Interests was -$1.0 million for Q1 2026 at Tandem Diabetes Care, down from -$49000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $3.9 million in Q3 2024 and bottomed at -$2.5 million in Q4 2024.
- A 3-year average of $59375.0 and a median of -$73500.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2025 — Income from Non-Controlling Interests jumped 98.04% — and 2026, when it sank 342.79%.
- Tandem Diabetes Care's Income from Non-Controlling Interests stood at -$2.5 million in 2024, then soared by 98.04% to -$49000.0 in 2025, then tumbled by 1995.92% to -$1.0 million in 2026.
- Business Quant data shows TNDM's Income from Non-Controlling Interests at -$1.0 million in Q1 2026, -$49000.0 in Q4 2025, and $241000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.21 Bn | 176.92 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.90 Bn | 126.02 Bn | 3.81 Bn | - |
| 3 | Medtronic | 109.00 Bn | 99.78 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 68.62 Bn | 67.16 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 47.39 Bn | 43.72 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.44 Bn | 26.16 Bn | 1.98 Bn | 22.00 Mn |
| 7 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn | - |
| 8 | Smith & Nephew | 27.03 Bn | 26.46 Bn | - | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.43 Bn | 2.07 Bn | -5.85 Mn |
| 10 | Tandem Diabetes Care | 1.15 Bn | 578.13 Mn | 136.79 Mn | -1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 Mn |
| Dec 31, 2025 | -49,000.00 |
| Sep 30, 2025 | 241,000.00 |
| Jun 30, 2025 | -98,000.00 |
| Mar 31, 2025 | 423,000.00 |
| Dec 31, 2024 | -2.50 Mn |
| Sep 30, 2024 | 3.95 Mn |
| Jun 30, 2024 | -463,000.00 |
| Mar 31, 2021 | -38,000.00 |
| Mar 31, 2020 | 42,000.00 |
| Dec 31, 2019 | -14,000.00 |
| Sep 30, 2019 | -60,000.00 |
| Jun 30, 2019 | 101,000.00 |
| Mar 31, 2019 | 50,000.00 |
| Sep 30, 2018 | -19,000.00 |
| Jun 30, 2018 | 6,000.00 |
| Mar 31, 2017 | 1,000.00 |
| Dec 31, 2016 | 2,000.00 |
| Sep 30, 2016 | -6,000.00 |
| Jun 30, 2016 | -37,000.00 |